Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | CNR2 | P34972 | 4/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | NCF1 | P14598 | 1/20 | 0.48 |
| ▸ | NOS2 | P35228 | 1/20 | 0.48 |
| ▸ | BACE1 | P56817 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.45 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | PLG | P00747 | 1/20 | 0.44 |
| ▸ | PLAU | P00749 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5729637 | 0.98 | MGAM (0.55) | MGAMALDH1A1MAPTGAACNR2 | |
| Hydrochloric Acid SCHEMBL6009217 | 0.98 | MGAM (0.55) | MGAMALDH1A1MAPTGAACNR2 | |
| Acetic Acid SCHEMBL17984568 | 0.89 | MGAM (0.61) | MGAMALDH1A1MAPTGAACNR2 | |
| SCHEMBL367913 | 0.79 | MGAM (0.68) | MGAMALDH1A1MAPTGAACNR2 | |
| SCHEMBL29540332 | 0.79 | MGAM (0.68) | MGAMALDH1A1MAPTGAACNR2 | |
| SCHEMBL867190 | 0.79 | LMNA (0.59) | MGAMALDH1A1MAPTGAACNR2 | |
| SCHEMBL4903234 | 0.79 | ALDH1A1 (0.64) | MGAMALDH1A1MAPTGAACNR2 | |
| SCHEMBL24565009 | 0.78 | MGAM (0.47) | MGAMALDH1A1MAPTGAACNR2 | |
| SCHEMBL5788456 | 0.78 | MGAM (0.66) | MGAMALDH1A1MAPTGAACNR2 | |
| Hydrochloric Acid SCHEMBL3401098 | 0.78 | MGAM (0.66) | MGAMALDH1A1MAPTGAACNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100475207-C | 1H-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseases | NOVARTIS AG (CH) | 2009-04-08 | — | — | CN | claimed |
| CN-1655788-A | 1H-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseases | NOVARTIS AG (CH) | 2005-08-17 | — | — | CN | claimed |
| EP-1425015-A4 | TETRAHYDROQUINOLINE DERIVATIVES AS ANTITHROMBOTIC AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2004-12-15 | — | — | EP | claimed |
| EP-1425015-A2 | TETRAHYDROQUINOLINE DERIVATIVES AS ANTITHROMBOTIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-06-09 | — | — | EP | claimed |
| WO-2003015715-A2 | TETRAHYDROQUINOLINE DERIVATIVES AS ANTITHROMBOTIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-02-27 | — | — | WO | claimed |
| JP-1066181-A | — | — | None | — | — | JP | disclosed |
| EP-3497094-B1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2023-02-15 | — | — | EP | disclosed |
| CN-113491766-A | Vaccine compositions and methods for restoring function of the NKG2D pathway against cancer | 达纳－法伯癌症研究所公司 | 2021-10-12 | — | — | CN | disclosed |
| CN-108699041-B | Imidazole derivative having JNK inhibitory activity and use thereof | 三进制药株式会社 | 2021-03-26 | — | — | CN | disclosed |
| EP-3409668-B1 | NOVEL IMIDAZOLE DERIVATIVE HAVING JNK INHIBITORY ACTIVITY AND USE THEREOF | SAMJIN PHARM CO LTD (KR) | 2020-10-21 | — | — | EP | disclosed |
| CN-110099898-A | compound and use thereof | 优曼尼蒂治疗公司 | 2019-08-06 | — | — | CN | disclosed |
| US-10301291-B2 | Imidazole derivative having JNK inhibitory activity and use thereof | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 2019-05-28 | — | — | US | disclosed |
| CN-100475207-C | 1H-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseases | NOVARTIS AG (CH) | 2009-04-08 | — | — | CN | disclosed |
| CN-101171254-A | Fused thieno[2,3-B]pyridine and thiazolo[5,4-B]pyridine compounds for inhibiting KSP kinesin activity | SCHERING CORP (US) | 2008-04-30 | — | — | CN | disclosed |
| WO-2007072041-A1 | THERAPEUTIC COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2007-06-28 | — | — | WO | disclosed |
| CN-1655788-A | 1H-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseases | NOVARTIS AG (CH) | 2005-08-17 | — | — | CN | disclosed |
| EP-1425015-A4 | TETRAHYDROQUINOLINE DERIVATIVES AS ANTITHROMBOTIC AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2004-12-15 | — | — | EP | disclosed |
| EP-1425015-A2 | TETRAHYDROQUINOLINE DERIVATIVES AS ANTITHROMBOTIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-06-09 | — | — | EP | disclosed |
| WO-2003015715-A2 | TETRAHYDROQUINOLINE DERIVATIVES AS ANTITHROMBOTIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-02-27 | — | — | WO | disclosed |
| JP-S6466181-A | QUINOLYPYRIMIDINE DERIVATIVE, ITS PRODUCTION AND PLANT BLIGHT CONTROLLING AGENT CONTAINING SAID DERIVATIVE AS ACTIVE COMPONENT | SUMITOMO CHEMICAL CO | 1989-03-13 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10301291-B2 | Imidazole derivative having JNK inhibitory activity and use thereof | MAPKAPK2, MAPKAPK3, MAP3K7 | MGAM 3555/4885ALDH1A1 3334/4885MAPT 237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.